Medtronic (MDT) Q3 2026 earnings review
PFA Supercycle Drives 10-Quarter High, But Diversification Lags
Medtronic delivered its strongest organic revenue growth in ten quarters (+6.0%), beating guidance by 50 basis points. The story is dominated by a single massive driver: Cardiac Ablation Solutions, which exploded 80% YoY driven by the Pulsed Field Ablation (PFA) launch. Non-GAAP EPS of $1.36 beat expectations by $0.03. However, the victory is lopsided—Cardiovascular (+10.6%) is carrying the company while Neuroscience (+2.5%) and Medical Surgical (+2.7%) significantly lagged the corporate average. Management reiterated FY26 guidance, signaling confidence in sustaining this momentum despite a $185M tariff headwind.
🐂 Bull Case
Cardiac Ablation Solutions grew 80% globally and 137% in the U.S. The PulseSelect and Sphere-9 technologies are driving a massive replacement cycle in the electrophysiology market, a trend likely to persist for several quarters.
Diabetes revenue grew 8.3% organic (14.8% reported), led by double-digit international strength. The business has definitively shifted from a drag on growth to an accretive driver.
🐻 Bear Case
Neuroscience (+2.5%) and Medical Surgical (+2.7%) are growing well below the corporate average of 6%. If the Cardiovascular supercycle cools, the rest of the portfolio is currently too sluggish to pick up the slack.
Management confirmed a ~$185M impact from tariffs for FY26. While included in guidance, this remains a volatile external risk factor for margins.
⚖️ Verdict: 🟢
Bullish. The revenue acceleration is real and funded by a product cycle (PFA) that is just getting started. While the lag in Neuroscience is a concern, the sheer magnitude of the Cardiovascular beat ($3.46B segment revenue) provides a substantial buffer.
Key Themes
The PFA Supercycle
Pulsed Field Ablation (PFA) has fundamentally altered Medtronic's growth profile. Cardiac Ablation Solutions revenue jumped 80% globally and 137% in the U.S. This is an acceleration from ~50% in Q1 and ~70% in Q2. This single product line is effectively lifting the entire Cardiovascular portfolio to double-digit organic growth (+10.6%).
Neuroscience Deceleration
Decelerating. Neuroscience, previously a reliable mid-single-digit grower, slowed to 2.5% organic growth in Q3 (down from ~4% in Q2 and 5.2% in FY25Q4). While Cranial & Spinal managed 3.7%, Specialty Therapies was flat (-0.2% reported). This segment needs to re-accelerate to diversify risk away from Cardiovascular.
Robotic Surgery Approvals
Significant regulatory wins for the Hugo robotic-assisted surgery system. FDA clearance was secured for general surgery and the first cases were completed this month. Additionally, the Stealth AXiS system for spinal procedures was cleared. These approvals pave the way for the Medical Surgical and Neuroscience segments to potentially accelerate in FY27.
Tariff Headwinds
The company maintained its estimate of a ~$185M tariff impact for FY26. While guidance was maintained excluding this impact (or rather, absorbing it), it represents a drag on earnings power equivalent to ~4.5% of EPS growth potential.
Diabetes International Strength
Diabetes revenue grew 14.8% reported and 8.3% organic. The growth is heavily skewed towards international markets (likely due to earlier 780G adoption), which grew double-digits. The U.S. launch of Simplera Sync and Instinct sensors remains the key catalyst to watch for domestic acceleration.
Other KPIs
Stable. Margin remained flat sequentially at 24.1% (vs 24.1% in Q2). GAAP operating margin was significantly lower at 16.2%, reflecting amortization and restructuring charges. The company is balancing the PFA launch costs with efficiency gains.
Accelerating. Calculated as Operating Cash Flow ($4.76B) minus CapEx ($1.42B). This compares to $3.12B in the prior year period, showing improved cash generation despite heavy investment in product launches.
Accelerating. Up 10.6% organic YoY. This segment is now generating nearly 40% of total company revenue and growing 4x faster than the other major segments.
Guidance
Stable. Guidance reiterated. With Q3 at 6.0% and YTD at 5.4%, this implies Q4 growth will likely remain in the 5.5-6.0% range. This is an acceleration from the ~5.0% guidance given earlier in the year.
Stable. Guidance reiterated. This includes the ~$185M tariff impact. The midpoint ($5.64) implies roughly 4-5% growth over FY25 ($5.20-$5.50 range historically). Excluding tariffs, growth would be ~4.5% higher.
Key Questions
Neuroscience Weakness
Neuroscience organic growth decelerated to 2.5% this quarter. Is this purely a comp issue, or are there competitive share losses in Cranial & Spinal Technologies?
PFA Sustainability
With U.S. Cardiac Ablation growing 137%, how much of this is stocking capital equipment vs. recurring consumable utilization? When do you expect this growth rate to normalize?
Margin Progression
Despite highest revenue growth in 10 quarters, operating margins are flat sequentially. When will the PFA volume leverage drop through to the bottom line?